Leitat Sets Course for 9.6 Million with Its Health Division by 2024

Leitat steps on the accelerator. The national and international technology centre is facing the final stretch of the year with the aim of increasing its turnover to double digits, both for its health department and for the entire hub.

Specifically, Leitat expects its research and development division to generate revenues of 9.6 million euros this year, which will represent 20% of the centre’s total income.

According to Marca Masa, director of the Health&Biomedicine Department, Leitat expects to maintain its global growth rate of between 5% and 7% annually and end the year with a total turnover of 48 million euros.

“We are betting on the organic growth of our team, maintaining our infrastructure and continuing to analyse the main markers of the technology centre,” said Masa.

Leitat plans to generate global revenues of 48 million this year

The Leitat health department was founded in 2009 with a preclinical focus and is currently the only non-profit foundation in Spain specialising in experimental health.

Specifically, the health division has two research areas : development of new therapies and a specialised area in health predictors. Leitat carries out its work in different areas and its main vocation is to provide companies with technologies such as molecular studies, for example.

Located in Barcelona’s science park, Leitat also has centres at the Vall d’Hebron Hospital and at the La Fe University and Polytechnic Hospital in Valencia. The hub has 500 employees , 50 of whom are involved in the health division, including biologists, biopharmaceutical specialists, chemists, etc.

The plans of Leitat’s health division include continuing to grow in printing medicine to create personalized treatments. In addition, the center will continue to develop biotrispecific antibodies, ideal for the oncology sector.

The centre has been collaborating with FC Barcelona for several years in the prediction of muscle injuries

Among the companies Leitat has worked with are Ipra, with which it has developed a vaccine, and FC Barcelona, ​​for which it has developed a system that allows the measurement of possible muscle injuries with a urine sample. Leitat has been collaborating with the football club for seven years, specifically with the women’s team, with results of up to 70% effectiveness in prediction.

Another project that the technology centre has been working on is the development of organoids. “Following the FDA’s approval that the use of animals is not strictly necessary, we are betting on this type of technology for our research,” the director emphasises.

__

(Featured image by Enes via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us